US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
The trial enrolled 238 adults from 104 international sites, comprising 190 patients in the AChR+ group and 48 patients in the MuSK+ group. Credit: shutterstock / CGN089. Amgen’s Uplizna ...
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or ...
BALTIMORE, Feb. 12, 2025 /PRNewswire/ -- Today, Previse, a gastrointestinal health company, announced a newly published study in the American Journal of Gastroenterology, which provides additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback